ClinicalTrials.gg
CompletedNCT02927262Updated Nov 26, 2024Results posted

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

A Phase 2 interventional study of Gilteritinib and Placebo in Acute Myeloid Leukemia (AML) and Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation, sponsored by Astellas Pharma Global Development, Inc.. Completed at 73 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.

Enrollment
15th of 31
98 · median 97
Started
2017
with 2 others
Phase 2
6 of 31
4 open now
Registered
8th of 31
by date
Lead sponsor
10 of 31
Astellas Pharma Global Development, Inc.

Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 15th largest by enrollment, is one of 3 that started in 2017, is one of 6 in phase 2, and was the 8th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About gilteritinib

gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study was to compare relapse-free survival (RFS) between participants with FMS-like tyrosine kinase 3 (FLT3) / internal tandem duplication (ITD) acute myeloid leukemia (AML) in first complete remission (CR1) and who were randomized to receive gilteritinib or placebo beginning after completion of induction/consolidation chemotherapy for a two-year period.

Read the detailed description

Participants in CR1 were approached for this study after induction/consolidation therapy was complete and a decision not to proceed with transplantation was made or a suitable donor could not be identified. Participants were randomized in a 2:1 ratio to receive gilteritinib or placebo. Participants entered the screening period up to 14 days prior to the start of treatment. Participants were administered treatment over continuous 28-day cycles. Gilteritinib or placebo was given daily for up to 2 years. After treatment discontinuation, participants had a 30-day follow-up visit for safety, after which the participants entered the long-term follow up period for collection of subsequent AML treatment, remission status, and survival (cause of death and date of death). Final database lock will occur when last subject last follow-up visit is reached, per protocol. Study drug was not provided during the follow-up period.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation

Keywords

  • Acute myeloid leukemia
  • First Complete Remission
  • gilteritinib
  • FLT3/ITD
  • AML
  • ASP2215
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is considered an adult according to local regulation at the time of obtaining consent form (ICF).
  • Subject consents to allow access to subject's diagnostic bone marrow aspirate or peripheral blood sample and/or the DNA derived from that sample, if available, that may be used to validate a companion diagnostic test for gilteritinib.
  • Subject has confirmed morphologically documented AML, excluding acute promyelocytic leukemia (APL), in CR1 (including CRp and CRi). For the purposes of enrollment, CR will be defined as \< 5% blasts in the bone marrow with no morphologic characteristics of acute leukemia (e.g., Auer rods) in the bone marrow with no evidence of extramedullary disease such as central nervous system involvement or granulocytic sarcoma.
  • Subject will not proceed with transplantation as either a decision not to proceed with transplantation has been made either on the recommendation of the treating physician or by the patient or a suitable donor could not be identified.
  • Subject is \< 2 months from the start of the last cycle of consolidation and should have completed the recommended number of consolidations per local practice.
  • Subject has had no use of agents, with the exception of FLT3 inhibiting agents during induction and/or consolidation therapy, within the prior 4 weeks.
  • Subject has had presence of the FLT3/ITD activating mutation in the bone marrow or peripheral blood as determined by the local institution at diagnosis.
  • Subject has an performance status 0 to 2.
  • Subject must meet the following criteria as indicated on the clinical laboratory tests:

    • Serum creatinine ≤ 1.5 x institutional (ULN), or if serum creatinine outside normal range, then (GFR) > 40 mL/min/1.73m\^2 as calculated with the 4-parameter Modification of Diet in Renal Disease (MDRD) equation.
    • Serum total ≤ 2.5 mg/dL (43 μmol/L), except for subjects with Gilbert's syndrome.
    • Serum (AST) and alanine aminotransferase (ALT) \< 3 x ULN.
    • Serum potassium and serum magnesium ≥ institutional lower limit of normal (LLN).
    • (ANC) ≥ 500/μl and ≥ 20000/μl (unsupported by transfusions).
  • Subject is suitable for oral administration of study drug.
  • Female subject must either:

    • Be of nonchildbearing potential:
    • (defined as at least 1 year without any menses) prior to screening, or
    • Documented surgically sterile or status posthysterectomy (at least 1 month prior to screening)
    • Or, if of ,
    • Agree not to try to become pregnant during the study and for 6 months after the final study drug administration
    • And have a negative urine or serum pregnancy test at screening
    • And, if heterosexually active, agree to consistently use highly effective per locally accepted standards (in addition to a barrier method) starting at screening and throughout the study period and for 6 months after the final study drug administration.
  • Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 2 months and 1 week after the final study drug administration.
  • Female subject must not donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration.
  • Male subject and subject's female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards (in addition to a barrier method) starting at screening and continue throughout the study period and for 4 months and 1 week after the final study drug administration.
  • Male subject must not donate sperm starting at screening and throughout the study period and for 4 months and 1 week after the final study drug administration.
  • Subject agrees not to participate in another interventional study while on treatment.

Exclusion criteria

Exclusion Criteria:

  • Subject has had prior transplant.
  • Subject has interval > 450 msec (average of triplicate determinations based on central reading).
  • Subject with Long QT Syndrome.
  • Subject with hypokalemia and hypomagnesemia at screening (defined as values below LLN).
  • Subject has clinically active central nervous system leukemia.
  • Subject is known to have infection.
  • Subject has active or C.
  • Subject has an uncontrolled infection. If a bacterial or viral infection is present, the subject must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to randomization. If a fungal infection is present, the subject must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to randomization.
  • Subject has progressing infection defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
  • Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, congestive heart failure (NYHA) class 3 or 4 or subject has a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multigated acquisition () scan performed within 1 month prior to study entry results in a left ventricular ejection fraction that is ≥ 45%.
  • Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP) 3A.
  • Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P-glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
  • Subject requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
  • Subject has a serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Subject has prior , except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent \< 5 years previously will not be allowed.
  • Subject has any condition which makes the subject unsuitable for study participation.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    Gilteritinib

    Participants received gilteritinib 120 mg (three tablets of 40 mg) orally, once daily (QD) for up to 2 years or until a protocol-specified discontinuation criterion was met.

    Drug: Gilteritinib

  • Placebo comparator
    Placebo

    Participants received gilteritinib matching placebo orally, QD for up to 2 years or until a protocol-specified discontinuation criterion was met.

    Drug: Placebo

Interventions

  • Oral tablet

    Also known as: ASP2215

  • DrugPlacebo

    Oral tablet

06

What researchers measure

Primary outcomes

  1. Relapse-free Survival (RFS) Per Independent Review Committee (IRC) Adjudication

    RFS was defined as the time from the date of randomization until the date of documented relapse or death from any cause, whichever occurred first. Relapse after complete remission (CR) \[including complete remission with incomplete platelet recovery (CRp) and Complete remission with incomplete hematologic recovery (CRi)\], was defined as bone marrow blasts 5% or higher (not attributable to regenerating bone marrow), any circulating blasts, any extra-medullary blast foci as per Revised International Working Group (IWG) criteria. Participants were classified as: CRi, if they fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 × 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence was not required. CRp, if they achieved CR except for incomplete platelet recovery (\< 100 × 10\^9/L). RFS was estimated using Kaplan-Meier estimates. hazard ratio (HR), cox proportional hazards model (CHM)

    Time frame: From the date of randomization until the date of documented relapse, or death; (Median time on study drug was 427 days for gilteritinib group and 212 days for placebo group)

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization until the date of death from any cause. OS was estimated using Kaplan-Meiers method.

    Time frame: From the date of randomization until the date of death from any cause; (Median time on study drug was 427 days for gilteritinib group and 212 days for placebo group)

  2. Event-Free Survival (EFS)

    EFS was defined as the time from the date of randomization until the date of documented relapse or discontinuation of the treatment, or initiation of other anti-leukemic treatment or death from any cause, whichever occurred first. Relapse after CR (including CRp and CRi), was defined as bone marrow blasts 5% or higher (not attributable to regenerating bone marrow), any circulating blasts, any extra-medullary blast foci as per Revised IWG criteria. Participants were classified as: CRi, if they fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 × 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence was not required. CRp, if they achieved CR except for incomplete platelet recovery (\< 100 × 10\^9/L). EFS was estimated using Kaplan-Meier's method.

    Time frame: From date of randomization until the date of documented relapse or discontinuation of the treatment, or initiation of other anti-leukemic treatment or death from any cause; (Median time on study drug was 427 days for gilteritinib and 212 days for Placebo)

  3. Change From Baseline in Quantitative Minimal Residual Disease Measured as Log10-transformed Overall FLT3/ITD Mutation Ratio at Months 3, 6, 12, 24/End of Treatment (EoT)

    MRD was measured from bone marrow samples. FLT3/ITD mutation ratio was measured in relation to total FLT3. For a participant with multiple ITD mutations, the overall FLT3/ITD mutation ratio was calculated from the sum of all ITD mutations. Absence of Minimal Residual Disease (MRD) is defined as log10-transformed overall FLT3/ITD mutation ratio ≤ -4.

    Time frame: Baseline and months 3, 6, 12, 24/EoT

  4. Number of Participants With Adverse Events (AE)

    An AE is any untoward medical occurrence in a participant administered a study drug, which does not necessarily have to have a causal relationship with treatment. It can, be any unfavorable and unintended sign, symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product whether considered related to the medicinal product. An AE is considered "serious" if, it results in results in death, is life-threatening (an AE is considered "life-threatening" if, its occurrence places the participant at immediate risk of death, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, Requires inpatient hospitalization (except for planned procedures as allowed per study) or leads to prolongation of hospitalization. TEAE was defined as an AE observed after starting administration of the study drug through 30 days after the last dose.

    Time frame: From first dose date up to 30 days after last dose or data cut-off date 25-May 2021 (Maximum treatment duration was 744 days)

  5. Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score

    ECOG performance status was measured on an 6 point scale. 0-Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead. Number of participants with ECOG PS was reported. ECOG PS grades with zero participants were not reported.

    Time frame: Months 1, 2, 3, 4, 5, 6, 8, 10. 12, 14, 16, 18, 20, 22 and 24/EoT

07

Results

Posted Jun 27, 2022

Participant flow

Adult participants diagnosed with FMS-like tyrosine kinase 3 (FLT3)/internal tandem duplication (ITD) acute myeloid leukemia (AML) in first complete remission (CR1), including complete remission with incomplete platelet recovery (CRp) and complete remission with incomplete hematologic recovery (CRi) for whom a decision not to proceed with transplantation was made, or a suitable donor could not be identified, were enrolled in this study.

Treatment Period (Up to 744 Days)
Participant flow — Treatment Period (Up to 744 Days)
MilestoneGilteritinibPlacebo
Started6335
Completed2412
Not completed3923
Withdrew: Withdrawal by subject30
Withdrew: Death10
Withdrew: Treatment ended due to transplant procedure10
Withdrew: Physician decision10
Withdrew: Becomes eligible for and proceeds to transplant01
Withdrew: Participant relapsed and became eligible for and proceeded to transplant01
Withdrew: Randomized in error10
Withdrew: Participant was not eligible for the study10
Withdrew: Mrd positive01
Withdrew: Disease relapse2318
Withdrew: Adverse event71
Withdrew: Investigators decision to take participant off trial due to molecular relapse10
Withdrew: Clinicians decision as suspected relapse01
Long Term Follow-up (Up to 1201 Days)
Participant flow — Long Term Follow-up (Up to 1201 Days)
MilestoneGilteritinibPlacebo
Started6035
Did not enter long term follow up period30
Completed3521
Not completed2514
Withdrew: Withdrawal by subject02
Withdrew: Lost to follow-up20
Withdrew: Death2312

Outcome measures

PrimaryRelapse-free Survival (RFS) Per Independent Review Committee (IRC) Adjudication

RFS was defined as the time from the date of randomization until the date of documented relapse or death from any cause, whichever occurred first. Relapse after complete remission (CR) \[including complete remission with incomplete platelet recovery (CRp) and Complete remission with incomplete hematologic recovery (CRi)\], was defined as bone marrow blasts 5% or higher (not attributable to regenerating bone marrow), any circulating blasts, any extra-medullary blast foci as per Revised International Working Group (IWG) criteria. Participants were classified as: CRi, if they fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 × 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence was not required. CRp, if they achieved CR except for incomplete platelet recovery (\< 100 × 10\^9/L). RFS was estimated using Kaplan-Meier estimates. hazard ratio (HR), cox proportional hazards model (CHM)

Time frame:
From the date of randomization until the date of documented relapse, or death; (Median time on study drug was 427 days for gilteritinib group and 212 days for placebo group)
Reported as:
Median · Months
Relapse-free Survival (RFS) Per Independent Review Committee (IRC) Adjudication
MonthsGilteritinibPlacebo
Relapse-free Survival (RFS) Per Independent Review Committee (IRC) Adjudication24.02 (14.06 to NA)15.84 (3.02 to NA)
Statistical analysis
  • Gilteritinib vs Placebo · Log Rank · p = 0.163 · Hazard ratio (hr): 0.738 · 95% CI 0.407 to 1.336HR \& 95% CI are based on CHM. Assuming proportional hazards, HR \< 1 indicates a reduction in hazard rate in favor of gilteritinib arm. Stratification factors:age, geographic region, presence of MRD at screening, use of FLT3 inhibiting agents per IRT.
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization until the date of death from any cause. OS was estimated using Kaplan-Meiers method.

Time frame:
From the date of randomization until the date of death from any cause; (Median time on study drug was 427 days for gilteritinib group and 212 days for placebo group)
Reported as:
Median · Months
Overall Survival (OS)
MonthsGilteritinibPlacebo
Overall Survival (OS)NA (30.42 to NA)NA (43.56 to NA)
Statistical analysis
  • Gilteritinib vs Placebo · Log Rank · p = 0.627 · Hazard ratio (hr): 1.130 · 95% CI 0.540 to 2.364HR \& 95%CI are based on CHM. Assuming proportional hazards, HR \< 1 indicates a reduction in hazard rate in favor of gilteritinib arm. Stratification factors: age, geographic region, presence of MRD at screening, use of FLT3 inhibiting agents per IRT.
SecondaryEvent-Free Survival (EFS)

EFS was defined as the time from the date of randomization until the date of documented relapse or discontinuation of the treatment, or initiation of other anti-leukemic treatment or death from any cause, whichever occurred first. Relapse after CR (including CRp and CRi), was defined as bone marrow blasts 5% or higher (not attributable to regenerating bone marrow), any circulating blasts, any extra-medullary blast foci as per Revised IWG criteria. Participants were classified as: CRi, if they fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 × 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence was not required. CRp, if they achieved CR except for incomplete platelet recovery (\< 100 × 10\^9/L). EFS was estimated using Kaplan-Meier's method.

Time frame:
From date of randomization until the date of documented relapse or discontinuation of the treatment, or initiation of other anti-leukemic treatment or death from any cause; (Median time on study drug was 427 days for gilteritinib and 212 days for Placebo)
Reported as:
Median · Months
Event-Free Survival (EFS)
MonthsGilteritinibPlacebo
Event-Free Survival (EFS)14.06 (9.89 to 23.72)6.74 (2.86 to 21.95)
Statistical analysis
  • Gilteritinib vs Placebo · Log Rank · p = 0.296 · Hazard ratio (hr): 0.862 · 95% CI 0.510 to 1.455HR \& 95%CI are based on CHM. Assuming proportional hazards, HR \< 1 indicates a reduction in hazard rate in favor of gilteritinib arm. Stratification factors: age, geographic region, presence of MRD at screening, use of FLT3 inhibiting agents per IRT.
SecondaryChange From Baseline in Quantitative Minimal Residual Disease Measured as Log10-transformed Overall FLT3/ITD Mutation Ratio at Months 3, 6, 12, 24/End of Treatment (EoT)

MRD was measured from bone marrow samples. FLT3/ITD mutation ratio was measured in relation to total FLT3. For a participant with multiple ITD mutations, the overall FLT3/ITD mutation ratio was calculated from the sum of all ITD mutations. Absence of Minimal Residual Disease (MRD) is defined as log10-transformed overall FLT3/ITD mutation ratio ≤ -4.

Time frame:
Baseline and months 3, 6, 12, 24/EoT
Reported as:
Mean · Ratio
Change From Baseline in Quantitative Minimal Residual Disease Measured as Log10-transformed Overall FLT3/ITD Mutation Ratio at Months 3, 6, 12, 24/End of Treatment (EoT)
RatioGilteritinibPlacebo
Month 30.14 ± 0.960.14 ± 1.46
Month 60.07 ± 0.92-0.17 ± 0.79
Month 12-0.11 ± 0.60-0.34 ± 0.67
Month 24/EoT-0.12 ± 1.080.23 ± 1.63
Statistical analysis
  • Gilteritinib vs Placebo · ANCOVA · p = 0.970 (2-sided P-value from analysis of covariance (ANCOVA) including treatment, age group, geographic region and use of FLT3-inhibiting agents per IRT as fixed factors and baseline score as covariate.)
  • Gilteritinib vs Placebo · ANCOVA · p = 0.415 (2-sided P-value from ANCOVA including treatment, age group, geographic region and use of FLT3-inhibiting agents per IRT as fixed factors and baseline score as covariate.)
  • Gilteritinib vs Placebo · ANCOVA · p = 0.271 (2-sided P-value from ANCOVA including treatment, age group, geographic region and use of FLT3-inhibiting agents per IRT as fixed factors and baseline score as covariate.)
  • Gilteritinib vs Placebo · ANCOVA · p = 0.179 (2-sided P-value from ANCOVA including treatment, age group, geographic region and use of FLT3-inhibiting agents per IRT as fixed factors and baseline score as covariate.)
SecondaryNumber of Participants With Adverse Events (AE)

An AE is any untoward medical occurrence in a participant administered a study drug, which does not necessarily have to have a causal relationship with treatment. It can, be any unfavorable and unintended sign, symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product whether considered related to the medicinal product. An AE is considered "serious" if, it results in results in death, is life-threatening (an AE is considered "life-threatening" if, its occurrence places the participant at immediate risk of death, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, Requires inpatient hospitalization (except for planned procedures as allowed per study) or leads to prolongation of hospitalization. TEAE was defined as an AE observed after starting administration of the study drug through 30 days after the last dose.

Time frame:
From first dose date up to 30 days after last dose or data cut-off date 25-May 2021 (Maximum treatment duration was 744 days)
Reported as:
Number · Participants
Number of Participants With Adverse Events (AE)
ParticipantsGilteritinibPlacebo
TEAE5833
Drug-Related TEAE5120
TEAE before Relapse5728
Drug-Related TEAE before Relapse5115
Serious TEAE2414
Drug-Related Serious TEAE103
TEAE Leading to Death11
Drug-Related TEAE Leading to Death01
TEAE Leading to Withdrawal of Treatment156
Drug-Related TEAE Leading to Withdrawal of Treatment52
TEAE Leading to Dose Reduction151
Drug-Related TEAE Leading to Dose Reduction141
TEAE Leading to Dose Interruption354
Drug-Related TEAE Leading to Dose Interruption311
Grade 3 or Higher Treatment-Emergent Adverse Events4218
Grade 3 or Higher Drug-related TEAE334
Death2011
SecondaryNumber of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score

ECOG performance status was measured on an 6 point scale. 0-Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead. Number of participants with ECOG PS was reported. ECOG PS grades with zero participants were not reported.

Time frame:
Months 1, 2, 3, 4, 5, 6, 8, 10. 12, 14, 16, 18, 20, 22 and 24/EoT
Reported as:
Number · Participants
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score
ParticipantsGilteritinibPlacebo
Baseline: Grade 03922
Baseline: Grade 12313
Month 2: Grade 03818
Month 2: Grade 1169
Month 2: Grade 201
Month 3: Grade 03320
Month 3: Grade 1194
Month 3: Grade 201
Month 4: Grade 03716
Month 4: Grade 1126
Month 5: Grade 03517
Month 5: Grade 1114
Month 6: Grade 03217
Month 6: Grade 1112
Month 8: Grade 03212
Month 8: Grade 186
Month 8: Grade 210
Month 10: Grade 02914
Month 10: Grade 183
Month 12: Grade 02414
Month 12: Grade 1113
Month 14: Grade 02113
Month 14: Grade 193
Month 16: Grade 02211
Month 16: Grade 142
Month 16: Grade 220
Month 18: Grade 01913
Month 18: Grade 181
Month 20: Grade 01813
Month 20: Grade 171
Month 22: Grade 02011
Month 22: Grade 142
Month 24/EoT: Grade 03420
Month 24/EoT: Grade 1146
Month 24/EoT: Grade 210
Month 24/EoT: Grade 311
Month 24/EoT: Grade 411

Adverse events

Collected over From the date of randomization up to end of study (85 months and 9 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gilteritinib24/63 (38.1%)24/62 (38.7%)53/62 (85.5%)
Placebo12/35 (34.3%)14/35 (40%)32/35 (91.4%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventGilteritinibPlacebo
Acute myeloid leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)7/625/35
Febrile neutropeniaBlood and lymphatic system disorders2/621/35
HyperleukocytosisBlood and lymphatic system disorders0/621/35
NeutropeniaBlood and lymphatic system disorders1/621/35
Anal haemorrhageGastrointestinal disorders0/621/35
NauseaGastrointestinal disorders0/621/35
VomitingGastrointestinal disorders0/621/35
PyrexiaGeneral disorders0/621/35
InfluenzaInfections and infestations0/621/35
Back painMusculoskeletal and connective tissue disorders0/621/35
Most frequent other events
Showing 10 of 57
Most frequent other events
EventGilteritinibPlacebo
Blood creatine phosphokinase increasedInvestigations18/621/35
NauseaGastrointestinal disorders8/627/35
Neutrophil count decreasedInvestigations12/623/35
Platelet count decreasedInvestigations12/624/35
ThrombocytopeniaBlood and lymphatic system disorders11/624/35
NasopharyngitisInfections and infestations7/626/35
NeutropeniaBlood and lymphatic system disorders10/621/35
FatigueGeneral disorders10/623/35
CoughRespiratory, thoracic and mediastinal disorders9/622/35
AnaemiaBlood and lymphatic system disorders5/625/35

Baseline characteristics

The full analysis set (FAS) consisted of all participants who were randomized.

Age, Continuous
Age, Continuous(Years)GilteritinibPlaceboTotal
Mean61.4 ± 11.059.9 ± 13.960.9 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)GilteritinibPlaceboTotal
Female312051
Male321547
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GilteritinibPlaceboTotal
Hispanic or Latino639
Not Hispanic or Latino502979
Unknown or Not Reported7310
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GilteritinibPlaceboTotal
American Indian or Alaska Native000
Asian171027
Native Hawaiian or Other Pacific Islander000
Black or African American000
White382260
More than one race000
Unknown or Not Reported8311
Age (<60 or ≥60 years)
Age (<60 or ≥60 years)(Participants)GilteritinibPlaceboTotal
<60 years241337
≥60 years392261
Geographic Region
Geographic Region(Participants)GilteritinibPlaceboTotal
North America549
Europe402060
Rest of the world181129
Presence of MRD
Presence of MRD(Participants)GilteritinibPlaceboTotal
MRD = Yes8614
MRD = No552984
Use of FLT3-inhibitors
Use of FLT3-inhibitors(Participants)GilteritinibPlaceboTotal
Use of FLT3 Inhibitor = Yes121022
Use of FLT3 Inhibitor = No512576
08

Study locations

73 sites
  • Site US10017
    Gainesville, Florida 32610-0278, United States
  • Site US10030
    Jacksonville, Florida 32204, United States
  • Site US10012
    Chicago, Illinois 60612, United States
  • Site US10025
    Syracuse, New York 13210, United States
  • Site US10007
    Portland, Oregon 97239, United States
  • Site US10029
    Greenville, South Carolina 26615, United States
  • Site BR55002
    Goiania, Goias 74605-020, Brazil
  • Site CA15001
    Halifax, Nova Scotia B3H2Y9, Canada
  • Site CA15003
    Toronto, Ontario M5G 2M9, Canada
  • Site CZ42001
    Ostrava-Poruba, 70852, Czechia
  • Site DK45002
    Arhus, Region Midtjylland DK 8000, Denmark
  • Site FR33004
    Brest, Finistere 29609, France
  • Site FR33002
    Tours cedex 01, Indre-et-Loire 37044, France
  • Site FR33014
    Vandoeuvre les Nancy, Meurthe-et-Moselle 54511, France
  • Site FR33007
    Pierre-Benite, Rhone 69310, France
  • Site FR33001
    Bayonne, 64100, France
  • Site FR33009
    Mulhouse, 68070, France
  • Site FR33008
    Nice Cedex 2, 06189, France
  • Site DE49001
    Duisburg, Nordrhein-Westfalen 47166, Germany
  • Site DE49008
    Stuttgart, 70376, Germany
  • Site GR30010
    Athens, Attiki 10676, Greece
  • Site GR30004
    Thessaloniki, Kentriki Makedonia 57010, Greece
  • Site GR30009
    Athens, Greece
  • Site GR30007
    Larissa, Greece
  • Site HU36003
    Nyiregyhaza, Szabolcs-Szatmar-Bereg H-4400, Hungary
  • Site IL97205
    Jerusalem, Yerushalayim 91031, Israel
  • Site IT39011
    Milano, Lombardia 20141, Italy
  • Site IT39004
    Castelfranco Veneto (TV), Treviso 31033, Italy
  • Site IT39008
    Bergamo, 24127, Italy
  • Site IT39005
    Parma, Italy
  • Site IT39010
    Reggio Emilia, 42100, Italy
  • Site IT39002
    Roma, 161, Italy
  • Site JP81018
    Nagoya, Aichi, Japan
  • Site JP81025
    Matsuyama, Ehime, Japan
  • Site JP81002
    Yoshida-gun, Fukui, Japan
  • Site JP81024
    Sapporo, Hokkaido, Japan
  • Site JP81012
    Kobe, Hyogo, Japan
  • Site JP81004
    Kanazawa, Ishikawa, Japan
  • Site JP81009
    Yokohama, Kanagawa, Japan
  • Site JP81014
    Sendai, Miyagi, Japan
  • Site JP81023
    Shimotsuke, Tochigi, Japan
  • Site JP81011
    Tachikawa, Tokyo, Japan
  • Site JP81010
    Aomori, Japan
  • Site JP81017
    Okayama, Japan
  • Site KR82005
    Suwon-si, Gyeonggi-do 16499, Korea, Republic of
  • Site KR82014
    Bucheon-Si, Gyeonggido 14584, Korea, Republic of
  • Site KR82013
    Goyang, Gyeonggido 10408, Korea, Republic of
  • Site KR82008
    Namdong, Incheon Gwang'yeogsiv 405 760, Korea, Republic of
  • Site KR82003
    Hwasungun, Jeonranamdo 58128, Korea, Republic of
  • Site KR82012
    Seoul, Seoul Teugbyeolsi 06351, Korea, Republic of
  • Site KR82006
    Busan, 49241, Korea, Republic of
  • Site KR82009
    Seoul, 120-752, Korea, Republic of
  • Site PL48001
    Olsztyn, Warmińsko-mazurskie 10-228, Poland
  • Site PL48002
    Bydgoszcz, 85-168, Poland
  • Site PL48007
    Poznan, Poland
  • Site PT35106
    Coimbra, 3000, Portugal
  • Site PT35101
    Porto, 4200-072, Portugal
  • Site RO40005
    București, Romania
  • Site RS38102
    Belgrade, 11000, Serbia
  • Site ES34009
    Vitoria, Alava 01009, Spain
  • Site SE46003
    Stockholm, Stockholms Lan 171 76, Sweden
  • Site SE46002
    Lund, 221 85, Sweden
  • Site TW88605
    Kaohsiung, 112, Taiwan
  • Site TW88604
    Kaohsiung, 83301, Taiwan
  • Site TW88603
    Taipei, 114, Taiwan
  • Site GB44007
    Exeter, Devon EX2 5DW, United Kingdom
  • Site GB44019
    Plymouth, Devon PL6 8DH, United Kingdom
  • Site GB44006
    Cottingham, East Riding Of Yorkshire HU165JQ, United Kingdom
  • Site GB44018
    London, London, City Of WC1E 6BT, United Kingdom
  • Site GB44002
    Birmingham, B95SS, United Kingdom
  • Site GB44015
    Cardiff, CF4 4XN, United Kingdom
  • Site GB44020
    Leeds, LS9 7TF, United Kingdom
  • Site GB44004
    Nottingham, NG5 1PB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in May 2021, 52 months.

Results were first posted in Jun 2022, 1 year 1 month after primary completion.

Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 52 months is above that.

Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2016
First posted
Oct 7, 2016
StartActual
Jan 10, 2017
Primary completionActual
May 25, 2021
CompletionActual
Feb 19, 2024
Results first posted
Jun 27, 2022
Last update
Nov 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02927262
Responsible party
Sponsor
First posted
Oct 7, 2016
Start date
Jan 10, 2017
Primary completion
May 25, 2021
Completion
Feb 19, 2024
Results posted
Jun 27, 2022
Last update
Nov 26, 2024

Study contacts

Executive Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gilteritinib

Start the discussion